EGFR and head and neck squamous cell carcinoma: Some small molecular inhibitors of EGFR are also under investigation for the management of HNSCC, including selective inhibitors (e.g., gefitinib, erlotinib) and dual-target inhibitors (e.g., afatinib, lapatinib, and dacomitinib).